study in high risk patients switched from higher doses of other statins to Crestor on the percentage of patients reaching the new LDL-C target goal

Study identifier:NL401142

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

REALISTIC: Protocol for an observational study in high risk patients switched from higher doses of other statins to Crestor on the percentage of patients reaching the new EAS LDL-C target goal

Medical condition

Hypercholesterolemia

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

2650

Study type

Observational

Age

18 Years - 70 Years

Date

Study Start Date: 01 Sept 2004

Primary Completion Date: 01 Feb 2008

Study Completion Date: 01 Feb 2008

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1086&filename=CSR-NL401142.pdf
Download
CSR-NL401142.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca BV, Zoetermeer Medical Department CV

+31 79 3632284

Investigators

Principal Investigator

AstraZeneca Netherlands Medical Director

AstraZeneca